{"title":"Expanding the Phenotype and Genotype Spectrum of a Novel Mutation in Hypomyelinating Leukodystrophy-5 With a Review of the Literature on 42 Cases.","authors":"Sahar Bayat, Milad Gholami, Hamidreza Khodadadi, Mohammadreza Ghazavi, Jafar Nasiri, Majid Kheirollahi","doi":"10.32598/bcn.2024.6930.1","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hypomyelinating leukodystrophy-5 (HLD-5) is a rare multiple congenital anomaly with intellectual disability caused by an autosomal recessive mutation in the <i>FAM126A</i> gene. It is characterized by bilateral congenital cataracts, developmental delay, cerebellar ataxia, slowly progressive gait disturbance, and cognitive impairment. This study aims to contribute to a better understanding of HLD-5 by reviewing previous patients and introducing a novel variant in a new case.</p><p><strong>Methods: </strong>We subjected a case with an initial diagnosis of HLD-5 in an Iranian family. To identify the possible genetic cause(s), whole exome sequencing (WES) was conducted to detect exon mutations. Sanger sequencing was performed to verify the DNA sequence variants and co-segregation analysis. We predicted the potential deleterious effects of the novel mutation using in silico predictive tools.</p><p><strong>Results: </strong>WES identified a novel homozygous mutation (NM_032581: c.636_639del p.C213Dfs*7) in the <i>FAM126A</i> gene. The variant can cause premature termination of amino acid translation or affect mRNA expression.</p><p><strong>Conclusion: </strong>This study explained the clinical manifestations and molecular findings of HLD-5. Additionally, we reported a novel variant and some rare clinical features, such as exophthalmos and strabismus, in our proband for the first time. Further research is needed to clarify the molecular mechanisms underlying HLD-5 pathogenesis.</p>","PeriodicalId":8701,"journal":{"name":"Basic and Clinical Neuroscience","volume":"16 2","pages":"505-518"},"PeriodicalIF":1.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13318211/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic and Clinical Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/bcn.2024.6930.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Hypomyelinating leukodystrophy-5 (HLD-5) is a rare multiple congenital anomaly with intellectual disability caused by an autosomal recessive mutation in the FAM126A gene. It is characterized by bilateral congenital cataracts, developmental delay, cerebellar ataxia, slowly progressive gait disturbance, and cognitive impairment. This study aims to contribute to a better understanding of HLD-5 by reviewing previous patients and introducing a novel variant in a new case.
Methods: We subjected a case with an initial diagnosis of HLD-5 in an Iranian family. To identify the possible genetic cause(s), whole exome sequencing (WES) was conducted to detect exon mutations. Sanger sequencing was performed to verify the DNA sequence variants and co-segregation analysis. We predicted the potential deleterious effects of the novel mutation using in silico predictive tools.
Results: WES identified a novel homozygous mutation (NM_032581: c.636_639del p.C213Dfs*7) in the FAM126A gene. The variant can cause premature termination of amino acid translation or affect mRNA expression.
Conclusion: This study explained the clinical manifestations and molecular findings of HLD-5. Additionally, we reported a novel variant and some rare clinical features, such as exophthalmos and strabismus, in our proband for the first time. Further research is needed to clarify the molecular mechanisms underlying HLD-5 pathogenesis.
期刊介绍:
BCN is an international multidisciplinary journal that publishes editorials, original full-length research articles, short communications, reviews, methodological papers, commentaries, perspectives and “news and reports” in the broad fields of developmental, molecular, cellular, system, computational, behavioral, cognitive, and clinical neuroscience. No area in the neural related sciences is excluded from consideration, although priority is given to studies that provide applied insights into the functioning of the nervous system. BCN aims to advance our understanding of organization and function of the nervous system in health and disease, thereby improving the diagnosis and treatment of neural-related disorders. Manuscripts submitted to BCN should describe novel results generated by experiments that were guided by clearly defined aims or hypotheses. BCN aims to provide serious ties in interdisciplinary communication, accessibility to a broad readership inside Iran and the region and also in all other international academic sites, effective peer review process, and independence from all possible non-scientific interests. BCN also tries to empower national, regional and international collaborative networks in the field of neuroscience in Iran, Middle East, Central Asia and North Africa and to be the voice of the Iranian and regional neuroscience community in the world of neuroscientists. In this way, the journal encourages submission of editorials, review papers, commentaries, methodological notes and perspectives that address this scope.